COPENHAGEN (AFX) - NeuroSearch AS said it has decided to continue the development of the NS2330 compound and added its partner, Boehringer Ingelheim, will return all regulatory rights for the compound to NeuroSearch. Last August, Boehringer Ingelheim decided not to initiate Phase III clinical studies of NS2330 for the treatment of Alzheimer's and Parkinson's diseases, after Phrase II clinical studies did not meet the efficacy criteria.
